Flu-M Vaccine Indicated For More Age Groups

4 February 2021
As part of the Russian scientific and practical online conference “Controlled And Other Socially Significant Infections: Diagnostic, Treatment And Prevention”, the experts from the St. Petersburg Institute of Vaccines and Serums shared with their colleagues the results of studies of the Flu-M influenza vaccine in different age groups.

Ellina Ruzanova, Candidate of Biological Sciences, Head of Trial and Authorization Department, in her report “Results of Clinical Trials of the Flu-M Influenza Vaccine in Children Aged 6-17”, explained the specific features of clinical trials conducted by pediatricians. Dr. Ruzanova presented the results of a comparative assessment of acceptability, safety and immunogenicity of the Flu-M and the Ultrix® vaccines obtained during a single immunization of children aged 6 to 17. These data indicate good acceptability, safety and immunogenic properties (seroprotection rate, seroconversion rate and seroconversion factor) of the Flu-M vaccine.

Yulian Koromzin, Candidate of Biological Sciences, Expert of the Clinical Trial Department presented in his report “Influenza Vaccine For Those Aged 65+”  the results of a prospective, multicenter, double-blind, randomized, comparative clinical trial of the Flu-M and Ultrix® vaccines for immunogenicity and safety in volunteers aged above 60. The Flu-M vaccine meets the European and Russian requirements for all investigated indicators of immunogenicity. Each group consisted of 160 volunteers. Dr. Koromzin also emphasized the peculiarities of the immune system and the course of influenza in people over 65, the common complications and adverse effects of influenza.

Igor Krasilnikov, Professor, Doctor of Biological Sciences, Deputy Director of SPbSRIVS, in his report “Flu-M Tetra: Safety and Immunogenicity” paid attention to the peculiarities of the quadruple vaccine allowing to obtain a hypoallergenic product while maintaining the native conformation of the hemagglutinin protein thus ensuring high immunogenicity. A brief historical background to influenza pandemics and resulting human and economic losses accentuated the benefits of the quadruple vaccines.

As is known, the Flu-M vaccine is produced by the Saint Petersburg Institute of Vaccines and Serums of the FMBA of Russia, delivered as scheduled in the National Calendar of Preventive Vaccinations of the Russian Federation and for export. Authorization is now pending to indicate the Flu-M influenza vaccine for more age groups and is expected to be granted any time soon.